glp-1 weight loss how does it work GLP-1R Agonists for Why nuts are a smart

A statistically significant improvement in KCCQ-CSS was found in the semaglutide group compared with placebo, although the magnitude of improvement was numerically smaller than in STEP-HFpEF

Glutathione protects immune cells from damage

Acetyl-L-Carnitine and NRTI-associated neuropathy in HIV-infection 46

Patients who might be considered for GLP-1 therapy (within licensed indications) and who may experience secondary benefits for binge eating behaviours include: Individuals with binge eating disorder and type 2 diabetes , where GLP-1 agonists address the primary diabetes indication whilst potentially helping with eating patterns Those with BED and obesity who meet NHS eligibility criteria for weight management medications (as defined by NICE TA875 for semaglutide or TA664 for liraglutide, which are narrower than the marketing authorisation) Patients who have not responded adequately to psychological interventions such as cognitive behavioural therapy (CBT) and who have concurrent metabolic conditions Those experiencing significant food cravings and loss-of-control eating as part of their weight management challenges However, important cautions and considerations apply

Significant and Sustainable Weight Loss: This is the primary and most celebrated benefit